KR102366547B1 - 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 - Google Patents

항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Download PDF

Info

Publication number
KR102366547B1
KR102366547B1 KR1020187034043A KR20187034043A KR102366547B1 KR 102366547 B1 KR102366547 B1 KR 102366547B1 KR 1020187034043 A KR1020187034043 A KR 1020187034043A KR 20187034043 A KR20187034043 A KR 20187034043A KR 102366547 B1 KR102366547 B1 KR 102366547B1
Authority
KR
South Korea
Prior art keywords
delete delete
bdca2
concentration
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187034043A
Other languages
English (en)
Korean (ko)
Other versions
KR20190002563A (ko
Inventor
마크 알. 에이치. 크렙스
데이빗 다이
샨타누 슐레
다니아 라바
데이빗 마르틴
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Priority to KR1020227005469A priority Critical patent/KR20220028150A/ko
Publication of KR20190002563A publication Critical patent/KR20190002563A/ko
Application granted granted Critical
Publication of KR102366547B1 publication Critical patent/KR102366547B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187034043A 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Active KR102366547B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227005469A KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005469A Division KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Publications (2)

Publication Number Publication Date
KR20190002563A KR20190002563A (ko) 2019-01-08
KR102366547B1 true KR102366547B1 (ko) 2022-02-23

Family

ID=58672794

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020187034043A Active KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247007023A Ceased KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020227005469A Ceased KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020247007023A Ceased KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020227005469A Ceased KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Country Status (14)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (3) JP7045327B2 (enExample)
KR (5) KR102366547B1 (enExample)
CN (2) CN116850282A (enExample)
AU (2) AU2017258191B2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
AU2021391803A1 (en) * 2020-12-03 2023-07-06 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
IL321721A (en) * 2022-12-28 2025-08-01 Duality Biologics Shanghai Co Ltd Antidote conjugation against BDCA2 and its use
AU2024348487A1 (en) * 2023-09-28 2026-04-23 Nanjing Leads Biolabs Co., Ltd. Bdca2 monoclonal antibody, fusion protein composed of same and taci, and method and use therefor
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos

Also Published As

Publication number Publication date
AU2017258191B2 (en) 2024-06-13
MA44763A (fr) 2019-03-06
JP2019520316A (ja) 2019-07-18
IL262514B1 (en) 2025-08-01
CA3022116A1 (en) 2017-11-02
NZ747504A (en) 2025-08-29
MX2018012945A (es) 2019-03-06
EA201892443A1 (ru) 2019-04-30
KR20240033168A (ko) 2024-03-12
AU2024203240A1 (en) 2024-06-13
JP2024038308A (ja) 2024-03-19
CN116850282A (zh) 2023-10-10
KR20240159012A (ko) 2024-11-05
KR20250088784A (ko) 2025-06-17
IL262514A (en) 2018-12-31
WO2017189827A1 (en) 2017-11-02
BR112018072125A2 (pt) 2019-03-19
AU2017258191A1 (en) 2018-11-15
PH12018502278A1 (en) 2019-09-09
US20190284281A1 (en) 2019-09-19
KR20190002563A (ko) 2019-01-08
MX2023008075A (es) 2023-07-18
NZ787392A (en) 2025-08-29
CN109475623A (zh) 2019-03-15
CO2018012506A2 (es) 2018-12-14
JP2022084782A (ja) 2022-06-07
IL321561A (en) 2025-08-01
JP7045327B2 (ja) 2022-03-31
US20250289895A1 (en) 2025-09-18
MX2025000037A (es) 2025-02-10
EP3448425A1 (en) 2019-03-06
CN109475623B (zh) 2023-05-26
KR20220028150A (ko) 2022-03-08
IL262514B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
US20250289895A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
EP3883966B1 (en) Humanized anti-human-pd-1 antibody
JP6949718B2 (ja) 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物
US20220056135A1 (en) Bifunctional anti-pd-1/sirpa molecule
KR20210030366A (ko) 항-pd-1 항체 및 이의 용도
EP4095158A1 (en) Pharmaceutical composition containing anti-btla antibody and use thereof
CN112804989A (zh) 抗fgfr2抗体制剂
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
WO2024249568A1 (en) Alpha4beta7 integrin antibody compositions and methods of use
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
JP2025512032A (ja) Ｐｄ－１抗体を含有する安定した高濃度アルギニン製剤及びその使用方法
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
WO2025098341A1 (en) IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
BR112018072125B1 (pt) Composição farmacêutica e seringa, injetor ou bomba
EA053327B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
JP2025512031A (ja) Ｐｄ－１抗体を含有する安定した高濃度塩化ナトリウム製剤及びその使用方法
HK40102352A (en) Humanized anti-human-pd-1 antibody
HK40052955A (zh) 抗fgfr2抗体制剂
HK40060816B (en) Humanized anti-human-pd-1 antibody
HK40060816A (en) Humanized anti-human-pd-1 antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210616

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211118

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220221

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 4

End annual number: 4